U.S. FDA approves Ilumya (tildrakizumab-asmn) Injection for the treatment of Plaque Psoriasis


Company: Sun Pharmaceutical Industries Ltd.

Generic Name: tildrakizumab-asmn

Dosage: Injection, for Subcutaneous Use

Treatment For: Plaque Psoriasis

General information about Illumya

The U.S. Food and Drug Administration (FDA) has approved Ilumya (tildrakizumab-asmn), an interleukin-23 antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Ilumya is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).